Clinical trial

Ambroxol as a Disease-modifying Treatment in GBA-PD

NCT05287503

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-03-09

PhasePHASE2

Study timeline

Study start (actual)2022-03-09Date precision: day

Registry last updated2025-08-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Parkinson Diseaseunresolved

GBA Gene Mutationunresolved

Interventions

Ambroxol HydrochlorideDRUG · verified · RxNorm: ambroxol hydrochloride

Sponsors & collaborators

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Bestalead sponsor

IRCCS National Neurological Institute "C. Mondino" Foundationcollaborator

University of Campania Luigi Vanvitellicollaborator

Mapped research locations

MilanItaly1 NaplesItaly1 PaviaItaly1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05287503 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.